Rowachol, a proprietary "essential oil" preparation, has been on the market for over 25 years and is freely available on prescription in the United Kingdom. There have been several reports of patients' gall stones disappearing after prolonged treatment with Rowachol.' 2 We have previously shown that two capsules of it given three times a day for 48 hours3 lowers the lithogenic index of human bile. Rowachol, like the bile acids chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA), apparently reduces biliary cholesterol output relative to that of bile salts and phospholipids (and hence renders bile desaturated) by specifically inhibiting the activity of the enzyme controlling hepatic cholesterol synthesis, hydroxymethyl-glutamylcoenzyme A reductase (HMGCoAR).4 We decided to evaluate Rowachol as a possible cholelitholytic agent in a small number of patients with radiolucent gall stones. We report our preliminary findings.
Patients, methods, and results
Twenty-seven patients with gall stones either in the gall bladder or common bile duct, or both, were treated with Rowachol 1 capsule/10 kg body weight/ day. Three patients were withdrawn from the study. One of them continued to have frequent biliary colic, one defaulted from follow-up, and a third complained of soreness of her mouth three days after starting treatment 
